163 related articles for article (PubMed ID: 36006892)
1. Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care - an overview.
D'Onofrio G; Riva A; Amadori E; Lattanzi S; Rose K; Verrotti A; Striano P
Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):575-585. PubMed ID: 36006892
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate-Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society.
Frontera JA; Gilmore EJ; Johnson EL; Olson D; Rayi A; Tesoro E; Ullman J; Yuan Y; Zafar SF; Rowe S
Neurocrit Care; 2024 Jun; 40(3):819-844. PubMed ID: 38316735
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Szaflarski JP; Sangha KS; Lindsell CJ; Shutter LA
Neurocrit Care; 2010 Apr; 12(2):165-72. PubMed ID: 19898966
[TBL] [Abstract][Full Text] [Related]
4. Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage.
Murphy-Human T; Welch E; Zipfel G; Diringer MN; Dhar R
World Neurosurg; 2011 Feb; 75(2):269-74. PubMed ID: 21492729
[TBL] [Abstract][Full Text] [Related]
5. Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy.
Schelhaas M; Wegner I; Edens M; Wammes-Van Der Heijden E; Touw D; Ter Horst P
Neurology; 2023 Jan; 100(2):e172-e181. PubMed ID: 36257713
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis.
Xu JC; Shen J; Shao WZ; Tang LJ; Sun YZ; Zhai XF; Qi L; Li J; Zheng JY
Brain Inj; 2016; 30(9):1054-61. PubMed ID: 27295203
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Levetiracetam in neonatal seizures: a systematic review.
Sharma D; Hussain AM; Sharma SS
J Matern Fetal Neonatal Med; 2022 Oct; 35(20):3923-3930. PubMed ID: 33172319
[TBL] [Abstract][Full Text] [Related]
8. Levetiracetam Versus Phenytoin for Seizure Prophylaxis Following Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
Yang Y; Zheng F; Xu X; Wang X
CNS Drugs; 2016 Aug; 30(8):677-88. PubMed ID: 27395404
[TBL] [Abstract][Full Text] [Related]
9. Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam.
Kruer RM; Harris LH; Goodwin H; Kornbluth J; Thomas KP; Slater LA; Haut ER
J Crit Care; 2013 Oct; 28(5):883.e9-13. PubMed ID: 23566730
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam, from broad-spectrum use to precision prescription: A narrative review and expert opinion.
Celdran de Castro A; Nascimento FA; Beltran-Corbellini Á; Toledano R; Garcia-Morales I; Gil-Nagel A; Aledo-Serrano Á
Seizure; 2023 Apr; 107():121-131. PubMed ID: 37023625
[TBL] [Abstract][Full Text] [Related]
11. [Comparisons of efficacy and safety of levetiracetam versus phenytoin for seizure prophylaxis in patients with brain injury: a meta analysis].
Li JN; Chen YM
Zhonghua Yi Xue Za Zhi; 2016 Oct; 96(39):3170-3177. PubMed ID: 27852418
[No Abstract] [Full Text] [Related]
12. Levetiracetam: a new therapeutic option for refractory epilepsy.
Pinto A; Sander JW
Int J Clin Pract; 2003 Sep; 57(7):616-21. PubMed ID: 14529064
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra.
Wang QH; Cao JJ; Wang YY; Zhang MN; Liu LY; Wang J; Lu Q; He W; Shen YW; Chen HM; Luo XM; Chen Q; Zou LP
Seizure; 2022 Feb; 95():64-74. PubMed ID: 35007884
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study.
Iuchi T; Kuwabara K; Matsumoto M; Kawasaki K; Hasegawa Y; Sakaida T
J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1158-62. PubMed ID: 25511789
[TBL] [Abstract][Full Text] [Related]
15. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study.
Fuller KL; Wang YY; Cook MJ; Murphy MA; D'Souza WJ
Epilepsia; 2013 Jan; 54(1):45-57. PubMed ID: 22738092
[TBL] [Abstract][Full Text] [Related]
16. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam monotherapy for elderly patients with epilepsy.
Alsaadi TM; Koopmans S; Apperson M; Farias S
Seizure; 2004 Jan; 13(1):58-60. PubMed ID: 14741184
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug.
De Smedt T; Raedt R; Vonck K; Boon P
CNS Drug Rev; 2007; 13(1):57-78. PubMed ID: 17461890
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
Stephen LJ; Kelly K; Parker P; Brodie MJ
Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.
Rhee SJ; Shin JW; Lee S; Moon J; Kim TJ; Jung KY; Park KI; Lee ST; Jung KH; Yu KS; Jang IJ; Chu K; Lee SK
Epilepsy Res; 2017 May; 132():8-14. PubMed ID: 28279893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
